B
5.22
-0.09 (-1.69%)
| Previous Close | 5.31 |
| Open | 5.27 |
| Volume | 115,394 |
| Avg. Volume (3M) | 175,593 |
| Market Cap | 187,137,184 |
| Price / Sales | 54.75 |
| Price / Book | 0.720 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,133.43% |
| Diluted EPS (TTM) | -1.98 |
| Total Debt/Equity (MRQ) | 3.29% |
| Current Ratio (MRQ) | 13.68 |
| Operating Cash Flow (TTM) | -53.21 M |
| Levered Free Cash Flow (TTM) | -34.85 M |
| Return on Assets (TTM) | -19.54% |
| Return on Equity (TTM) | -30.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | BioAge Labs, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 66.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redpoint Management, Llc | 30 Jun 2025 | 383,254 |
| 52 Weeks Range | ||
| Median | 15.00 (187.36%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 29 Oct 2025 | 15.00 (187.36%) | Buy | 7.68 |
| 22 Oct 2025 | 10.00 (91.57%) | Buy | 6.05 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Sep 2025 | Announcement | HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor |
| 20 Aug 2025 | Announcement | BioAge Labs to Present at Upcoming Investor Conferences |
| 15 Aug 2025 | Announcement | BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor |
| 06 Aug 2025 | Announcement | BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |